Source: Manufacturing Chemist

BioReliance: Merck invests $109m in viral vector and gene therapy manufacturing

German Merck has announced a second Carlsbad, California facility to double its BioReliance viral and gene therapy service offering

Read full article »
BioReliance's Competitors | BioReliance's News | BioReliance's Financials
Stay up-to-date with the latest news on BioReliance
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
CEO Avatar

President & CEO

Charles C. Harwood, Jr

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on BioReliance